MyelinWatch EL
← Back to updates
Emerging treatmentsMyelin repair
Laboratory or animal researchLaboratory or animal programmeNo evidence of benefit in people yet

Laboratory and animal research

Rutgers advances new molecules that may help repair myelin

Worth knowing

Rutgers presented new small molecules that act on a receptor called mGluR5. They increased production of myelin proteins in human cells in the laboratory and showed activity in animal models.

What this means for people with MS

This is early research seeking a partner for further development, not a study in people. Researchers still need to select and improve the best candidate molecule.

What kind of evidence exists?
University research-development programme
How reliable is this source?
Official university source about research available for further development • not evidence from people

Related study or programme: Rutgers mGluR5 agonists →

University development sourceRead the source ↗

Related substantive developments

Myelin repair
Laboratory or animal researchLaboratory or animal programmePromising early finding

Laboratory and animal research

Blocking fibronectin restored remyelination in experimental models

A PNAS study found that a protein called fibronectin can build up in areas where myelin has been lost. This may trap immature cells that could otherwise become myelin-making cells. Blocking fibronectin improved myelin repair and symptoms in two animal models.

Read the update →Peer-reviewed paper
Emerging treatmentsMyelin repair
Registered study in peopleOngoing, but not accepting participantsNo evidence of benefit in people yet

Phase 3 study that can add or remove treatments

OCTOPUS: the first review of metformin and alpha-lipoic acid is planned for September 2026

The first OCTOPUS review in progressive MS will assess metformin and alpha-lipoic acid. It will look at brain shrinkage on MRI, disability, walking speed and hand function.

Read the update →University / investigator